Company intelligence / Profile preview

Calciscon

Biel/Bienne, Bern, Switzerland

Ownership: Private
Development stage: Other

Overview

Calciscon develops diagnostics for Calciprotein Particles (CPP), drivers of inflammation in chronic diseases like CKD. Their T50 test is CE-marked and predicts mortality in hemodialysis patients and type 2 diabetes. The company has raised CHF 2.5M in Series A funding and €2M in Eurostars funding.

Therapeutic areas: EndocrinologyNephrologyCardiovascular
Industry: Protein Biomarker Diagnostics

Partnerships

Fresenius Medical CareAmsterdam University Medical CenterAdmesy

Beyond the preview

Go deeper on Calciscon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calciscon.

Explore the full profile